Hydroxychloroquine non-availability during COVID-19 pandemic and its relation to anxiety level and disease activity in rheumatoid arthritis and lupus patients: a cross-sectional study

Mohammed Hassan Abu-Zaid1, Hany M. Aly2, Abdelhafeez Moshrif3, Doaa E. Abdeldaim4 and Nehal El-Ghobashy5*

Abstract

Background: During COVID-19 disease era, there is an accelerated demand for hydroxychloroquine since it was suggested by some centers as potential therapy for COVID-19 which has led to diminished supplies for patients with rheumatic disease and which carried unexpected risk for disease flare particularly in patients with systemic lupus erythematosus and rheumatoid arthritis. The purpose of the work is to detect the effect of HCQ shortage in patients with RA and SLE on anxiety and disease activity.

Results: A total of 320 patients were divided into two groups: group 1—216 RA patients with mean age 45.5 ± 9.59 years, disease duration 43.4 ± 25.6 months with female predominance (62.5%). Group 2—104 SLE patients with mean age 33.4 ± 7.9 age years, disease duration 52.1 ± 34.6 months with female predominance (85.6%). HCQ shortage occurred in 174 RA patients (80.5%) and 76 lupus patients (73.1%). Despite HCQ shortage, there were no significant change in disease activity of RA (using CDAI) and SLE (using SELENA) \( p = 0.063 \) and \( p = 0.064 \) respectively before and after HCQ shortage. Anxiety level was higher in patients who were exposed to HCQ shortage in both groups (SLE \( p = 0.0058 \) and RA \( p = 0.0044 \)) when we compared them to those without HCQ shortage.

Conclusion: In most patients with RA and SLE, the COVID-19 pandemic resulted in a HCQ scarcity, with no effect on disease activity. Anxiety was found to be associated with HCQ shortage in both diseases.

Background

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune condition that affects multiple body cells and has a high disease morbidity and mortality rate [1]. It is affected by degradation of autoreactive T cell immune tolerance and/or suppressive T cell dysfunction [2]. Systemic lupus erythematosus (SLE) is a multi-system autoimmune disorder that contributes significantly to global morbidity and mortality. It primarily affects women with a ratio of 10 to 1 between women and men during their reproductive life [3].

Hydroxychloroquine (HCQ) and chloroquine (CQ) are widely used anti-malarial drugs that elicit immunomodulatory effects and have a variety of mechanisms to aggregate in the lysosome and autophagosome of cells, and to impact antigen presentation and major histocompatibility
cells (MHCs) class II; they also inhibit the development of pro-inflammatory cytokines [4].

Throughout the globe, fears of HCQ supply constraints for rheumatic patients are increasing as an implication of the overwhelming science and public interest for HCQ as a possible COVID-19 medication, and this affects rheumatic patients who use HCQ in their therapeutic management [5].

Through COVID-19 infection, several studies of insomnia, psychiatric pain, anxiety, depression, and signs of traumatic stress in the common public in Asia and Europe have been reported [6–9]. Salari et al. stated in their systematic review and meta-analysis that the incidence of stress, anxiety, and depression is 29.6%, 31.9%, and 33.7%, respectively [9].

The aim of this study is to detect the influence of HCQ shortage on disease activity and anxiety in patients with RA and SLE during COVID-19 pandemic.

Methods

Study design

This cross-sectional multicenter study included 216 patients with rheumatoid arthritis (fulfilling the 2010 American College of Rheumatology (ACR) Classification criteria for Rheumatoid Arthritis) [10] and 104 lupus patients (fulfilling the 2012 SLICC classification criteria for SLE) [11] receiving Hydroxychloroquine were included in this cross-sectional multicenter study. Patients were recruited from outpatient clinics of rheumatology and rehabilitation departments of our university hospitals.

Patients who did not have HCQ in their treatment regimen and patients with known psychological disorders or severe debilitating disease were excluded from the study.

In this study, all participants were subjected to history taking and clinical examination. The laboratory investigations of relevance were assessed including erythrocyte sedimentation rate (ESR) and autoimmune profile of importance.

Clinical disease assessment data were recorded twice:

1- Before HCQ shortage (from data of patients recorded in their medical files)
2- Three months after HCQ shortage.

Methods of assessment of the patients:

1- Assessment of incidence of HCQ shortage by asking the patient the following questions:

Have you faced any difficulty in finding HCQ? If yes.
Have you stopped HCQ because of its shortage?

1- Clinical assessment of disease activity was done using the following:

- Clinical Disease Activity Index (CDAI) [12].
- SLEDAI-SLE disease activity index (SELENA modification) [13].

2- Assessment of anxiety by Hamilton anxiety rating scale (14 questions with a total score range of 0–56) [14].

Statistical analysis

Statistical Package for Social Sciences (SPSS) (version 23.0, IBM, Armonk, NY) was used to analyze the data of the study. Descriptive presentations were done for all variables of the study and comparison between groups was done by using chi-square test ($\chi^2$). Quantitative variables were presented by mean and standard deviation and comparison between them was done by independent $t$ test. Comparison between data before and after COVID-19 in the same group was done by paired $t$ test. Level of significance was at $p \leq 0.05$.

Results

This study included 216 RA patients and 104 lupus patients. Most of patients were female and with mean age of 45.5 ± 9.59 years and 33.4 ± 7.9 years respectively. Most of patients were married with disease duration 43.4 ± 25.6 months and 52.1 ± 34.6 months respectively. Most of RA patients received methotrexate and low dose corticosteroids, while most of SLE patients received corticosteroids and either azathioprine or mycophenolate mofetyl. HCQ shortage occurred in 174 RA patients (80.5%), and 76 lupus patients (73.1%), with mean duration of shortage 103.2 ± 49.4 and 88.6 ± 23.7 days respectively. The demographic and clinical data of both groups were represented in Table 1.

By using dependent $t$ test to compare disease activity before and after HCQ shortage, there were no significant changes in disease activity of RA (using CDAI), and SLE (using SELENA) $p = 0.063$ and 0.064 respectively. This was explained in Table 2.

Anxiety level was higher in patients who exposed to HCQ shortage in both groups when we compared them to those unexposed to HCQ shortage, and this was explained in details in Tables 3 and 4.

There was significant positive correlation between anxiety level and CDAI in group I ($P = 0.006$); also, there was significant positive correlation between anxiety level and SELSNA in group II ($P = 0.009$) (Table 5).
From the logistic regression model to evaluate the factors associated with anxiety, we observed that anxiety was significantly associated with HCQ shortage, the duration of shortage, CDAI, and SELENA. Table 6 mentions these associations in details.

Table 1 Demographic and clinical data of both groups

| Age (years) mean ± SD | Group I: RA patients (216) | Group II: SLE patients (104) |
|-----------------------|---------------------------|-----------------------------|
| Sex (M/F)             | 45.5 ± 9.59               | 33.4 ± 7.9                  |
| Residence             | 81/135                    | 15/89                       |
| Marital status        | Urban/rural               | 108/108                     |
|                       | Married/not married       | 207/9                       |
| Disease duration (months) Mean ± SD | 43.4 ± 25.6 | 52.1 ± 34.6 |
| Disease presentation (number of patients) | Articular: 216 60 | Cutaneous: 0 98 |
|                       | Serositis: 4 56           | Nephritis: 0 31             |
|                       | Neuropsychiatric: 0 4     | Cardiac: 0 7                |
|                       | Hematological: 0 32       | Vasculitis: 1 3             |
|                       | Hypertension: 13 10       | APS: 0 6                    |
| Comorbidities (number of patients) | Hypertension: 13 10 | Diabetes: 8 3 |
|                       | Hyperlipidemia: 6 4       | Chronic kidney disease: 0 2 |
|                       | Interstitial lung disease: 2 1 | Thyroid dysfunction: 6 8 |
|                       | Hypocomplementemia: 0 46  | |
| HCQ shortage (Y/N)    | 174/42                    | 76/28                       |
| Duration of shortage (days) mean ± SD | 103.2 ± 49.4 | 88.6 ± 23.7 |
| Lab findings N (%)    | RF: 147 (68%)             | 5 (4.8%)                    |
|                       | Anti-CCP: 174 (80.5%)     | 0                           |
|                       | ANA: 12 (5.5%)            | 104 (100%)                  |
|                       | Anti-dsDNA: 0 84 (80.8%)  |                             |
|                       | Hypocomplementemia: 0 46  | 46 (44.2%)                  |
| Treatment received (number of patients) | Methotrexate: 135 3 | Leflunomide: 96 0 |
|                       | Azathioprine: 4 56        | Mycophenolate mofety: 0 45  |
|                       | Cyclophosphamide: 0 4     | Corticosteroids: 125 88     |
|                       | Biological therapy: 0 0   |                             |

HCQ hydroxychloroquine, RF rheumatoid factor, anti-CCP, anti-cyclic citrullinated peptide, ANA anti-nuclear antibody

**Discussion**

Over the decades, HCQ remains the pillar pharmacotherapy in treatment of variety of rheumatic disease. Patients with SLE who usually take HCQ experience improvement in overall disease activity, beyond lupus, patients with rheumatic disease who take HCQ advantage from improvement in their thrombotic risk, lipid profile, and glycemic index [15]. For a long time, the 1995 HERA study [16] demonstrated that it has a significant benefit on synovitis, pain, and physical disability in patients with early-stage RA.

Across the globe, concerns of hydroxychloroquine (HCQ) supply shortages for patients with rheumatic disease are growing [17] in part because of the immense scientific and public eagerness for HCQ as a potential COVID-19 therapy [18].

The demand surge for HCQ extremely influenced access to this drug among patients with SLE and RA [19]. The purpose of this study is to explore the effect of HCQ shortage on Egyptian SLE and RA patients.

In our study, we enrolled 320 patients from different four rheumatology departments representing different regions in Egypt (Cairo, Delta, and Upper Egypt). Our patients in RA group and SLE group experienced hydroxychloroquine shortage 80.5% and 73% respectively due to drug unavailability with no significant changes in disease activity of RA (using CDAI), and SLE (using SELENA) \( p = 0.063 \) and 0.064 respectively. In a study conducted by Abualfadl E et al., 41.8% of rheumatoid arthritis patients reported difficulty to obtain HCQ and about 40.7% experienced flare of their disease [20]. This difference could be attributed to difference in sample size between both studies. As regards SLE, our results agree with a report published by EULAR in 2021 which showed that 55% of patients with SLE experienced HCQ shortage during COVID-19 pandemic [21]. In a study by Gheita et al. on Egyptian patients in 2020, 90% of SLE patients and 50% of RA patients were exposed to HCQ non-availability [22].

Lupus patients already have exceptionally high levels of comorbid anxiety and depression, which are related to worse lupus outcomes and higher side-effect burden [23]. Further, there is mounting proof that psychological stress, as seen in depression and anxiety, may contribute to inflammation in SLE. In this study, anxiety level was higher in SLE patients who were exposed to HCQ shortage (\( p: 0.009 \)). Although we found positive correlation between anxiety level and SELENA (\( p: 0.0058 \)). In agreement to our results, Pawluk et al. followed 41 female SLE patients for 6 months and found that higher levels of daily stress were related to expanded disease activity as measured by the European consensus lupus activity measurement, and CH50 levels [24].
In a survey done by Cherica et al., 20% of the respondents with lupus and RA experienced moderate to severe psychological impact. There was moderate to severe anxiety in 38.7% and moderate to severe depression in 27% [25]. Regarding RA patients in this study, 15.5% of RA who found difficulty in getting HCQ had severe anxiety compared to 4.7% of RA patients that did not face this problem.

Our patients with SLE and RA are vulnerable group of patients due to their immunosuppressed status [26]. One other factor that may have contributed to the patients’ anxieties was the clashing reports on the effects (advantageous to hurtful) of hydroxychloroquine in COVID-19 patients [27]. In this study we evaluated factors associated with anxiety, and we observed that anxiety was significantly associated with HCQ shortage, the duration of shortage, CDAI, and SELENA.

HCQ shortage did not adversely affect our patient’s disease activity but lead to psychological impact on our patients, Knowing the psychological status of our patients and the factors influencing their mental status, thus, has provided insight and better understanding

| Table 2  | Disease activity before and after HCQ shortage |
|----------|-----------------------------------------------|
|          | Before shortage | After shortage | Paired t test | P value |
| CDAI in RA patients | 11.47 ± 5.62 | 12.51 ± 5.97 | 1.86 | 0.063 |
| SELENA in SLE patients | 4.86 ± 3.78 | 5.88 ± 4.11 | 1.86 | 0.064 |

*CDAI clinical disease activity index, RA rheumatoid arthritis, SELENA safety of estrogens in systemic lupus erythematosus national assessment, SLE systemic lupus erythematosus

*Significant P value if p < 0.05

| Table 3  | Anxiety “Hamilton Anxiety Rating Scale” in RA patients during COVID-19 outbreak |
|----------|--------------------------------------------------------------------------------|
|          | With HCQ shortage (174) | Without HCQ shortage (42) | P value |
| Anxiety level | 24.31 ± 9.6 | 19.73 ± 7.45 | 0.0044* |
| Mild | 33 (18.9%) | 16 (38.1%) | 0.031* |
| Mild to moderate | 58 (33.3%) | 13 (31%) |
| Moderate to severe | 56 (32.3%) | 11 (26.2%) |
| Severe | 27 (15.5%) | 2 (4.7%) |

*HCQ hydroxychloroquine

*Significant P value if p < 0.05

| Table 4  | Anxiety “Hamilton Anxiety Rating Scale” in SLE patients during COVID-19 outbreak |
|----------|--------------------------------------------------------------------------------|
|          | With HCQ shortage (76) | Without HCQ shortage (28) | P value |
| Anxiety level | 28.61 ± 10.83 | 22.11 ± 9.57 | 0.0058* |
| Mild | 5 (6.6%) | 8 (28.6%) | 0.006* |
| Mild to moderate | 22 (28.9%) | 11 (39.3%) |
| Moderate to severe | 33 (43.4%) | 6 (21.4%) |
| Severe | 16 (21.1%) | 2 (10.7%) |

*SLE systemic lupus erythematosus, HCQ hydroxychloroquine

*Significant P value if p < 0.05

| Table 5  | Correlation between anxiety “Hamilton Anxiety Rating Scale” and disease activity measurements |
|----------|--------------------------------------------------------------------------------|
|          | r | p |
| CDAI | 0.186 | 0.006* |
| SELENA | 0.254 | 0.009* |

*CDAI clinical disease activity index, SELENA safety of estrogens in systemic lupus erythematosus national assessment

*Significant P value if p < 0.05

| Table 6  | Relation between anxiety “Hamilton Anxiety Rating Scale” and different variables |
|----------|--------------------------------------------------------------------------------|
|          | OR | P value |
| Group I (RA) | | |
| Age | 0.98 | 0.13 |
| Sex | 1.1 | 0.17 |
| Marital status | 1.5 | 0.18 |
| Disease duration | 0.92 | 0.12 |
| HCQ stoppage | 1.9 | 0.03* |
| Duration of stoppage | 3.8 | 0.017* |
| CDAI | 1.09 | 0.01 |
| Group II (SLE) | | |
| Age | 2.1 | 0.02* |
| Sex | 0.45 | 0.09 |
| Marital status | 0.9 | 0.17 |
| Disease duration | 0.98 | 0.06 |
| HCQ stoppage | 1.6 | 0.03* |
| Duration of stoppage | 4.2 | 0.04* |
| SELENA | 1.1 | 0.02* |

*CDAI clinical disease activity index, RA rheumatoid arthritis, SELENA safety of estrogens in systemic lupus erythematosus national assessment, SLE systemic lupus erythematosus, HCQ hydroxychloroquine

Logistic regression test

*Significant P value if p < 0.05
of their needs and how best to assist them during these troublesome time

Conclusion
COVID-19 pandemic resulted in a lack of hydroxychloroquine supplies to the majority of RA and SLE patients, which did not adversely impact their disease activity due to presence of other drug alternatives. However, HCQ shortage was a risk factor for anxiety in those patients. Health care facilities should add HCQ to be a prescription medication to avoid unreasonable drug shortage.

Abbreviations
RA: Rheumatoid arthritis; SLE: Systemic lupus erythematosus; HCQ: Hydroxychloroquine; CQ: Chloroquine; MHC: Major histocompatibility; COVID-19: Coronavirus disease-19; ACR: American College of Rheumatology; ESR: Erythrocyte Sedimentation Rate; CDAD: Clinical Disease Activity Index; SLEDAI: Systemic Lupus Disease Activity Index.

Acknowledgements
Not applicable.

Authors’ contributions
Conceptualization and design, Mohammed Hassan Abu-Zaid, Hany Aly, Abdelhafez Moshrif, Doaa Abdelald, and Nehal El Ghoabasy. Acquisition of data: Nehal El Ghoabasy and Abdelhafez Moshrif. Formal analysis: Mohammed Hassan Abu-Zaid and Doaa Abdelald. Investigation: Hany Aly and Abdelhafez Moshrif. Methodology: Mohammed Hassan Abu-Zaid, Doaa Abdelald. Validation: Hany Aly and Abdelhafez Moshrif. Writing—original draft: Mohammed Hassan, Abu-Zaid, and Nehal El Ghoabasy. Final approval of the version to be submitted: Mohammed Hassan Abu-Zaid, Hany Aly, Abdelhafez Moshrif, Doaa Abdelald, and Nehal El Ghoabasy. All authors read and approved the final manuscript.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials
The data will be available upon reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the ethical committee of the Tanta Faculty of Medicine with acceptance number 33946/7/20 of the ethics board of the university. It is in accordance with the Helsinki Declaration’s legal principles. The local ethics commission received written informed consent from all patients. The privacy of all details of patients was granted, as each medical file contains a code number.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Rheumatology and Rehabilitation, Faculty of Medicine, Tanta University, Tanta, Egypt. 2 Rheumatology and Rehabilitation, Faculty of Medicine, Al-Azhar University (Cairo), Al-Mokhayam Al-daem St. Nasr City, Cairo, Egypt. 3 Rheumatology Department, Faculty of Medicine, Al-Azhar University (Assiut), 71524, Al-Azhar University Square, King Faisal, Assiut, Egypt. 4 Faculty of Medicine, Tanta University, Tanta, Egypt. 5 Faculty of Medicine, Cairo University, Cairo, Egypt. 6 Faculty of Medicine, Al-Azhar University (Assiut), 71524, Al-Azhar University Square, King Faisal, Assiut, Egypt. 7 Faculty of Medicine, Al-Azhar University ( Cairo), Al-Mokhayam Al-daem St. Nasr City, Cairo, Egypt.

Received: 6 January 2022 Accepted: 25 February 2022
Published online: 10 March 2022

References
1. Abu-Zaid MH, Ghany SEMA, Gaber RA (2018) Effect of statins as modulators of CD39+ tregs in patients with rheumatoid arthritis who were unsuccessfully treated with methotrexate. Egypt Rheumatol Rehabil 45:1–8
2. Nada DIW, El Morsy S, Abu-Zaid MH, Aboelhawa MA, Zakaria MA, El Sheikha EA et al (2018) The role of microalbuminuria as a predictor of subclinical cardiovascular events in rheumatoid arthritis patients and its relation to disease activity. Clin Rheumatol 37(3):623–630
3. Moghazy A, Ibrahim AM (2021) Mortality in a cohort of Egyptian systemic lupus erythematosus patients: retrospective two-center study. Egypt Rheumatol Rehabil 48:14
4. Tang C, Godfrey T, Stawell R, Nikpour M (2021) Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 42(9):968–978
5. Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet E et al (2021) Hydroxychloroquine shortages during the COVID-19 pandemic. Ann Rheum Dis 80:31
6. Salari N, Hosseinian-Far A, Jalali R, Vaisi-Ragany A, Rasoupoor S, Mohammdi M et al (2020) Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Glob Health 16(1):57. https://doi.org/10.1186/s12992-020-00589-w
7. Rajkumar RP (2020) COVID-19 and mental health: a review of existing literature. Asian J Psychiatr 52:102066. https://doi.org/10.1016/j.ajp.2020.102066
8. Wang C, Pan R, Wan X, Tan Y, Xu L, Ho CS et al (2020) Immediate psychological responses and associated factors during the initial stage of the 2019 coronavirus disease (COVID-19) epidemic among the general population in China. Int J Environ Res Public Health 17(3):1729. https://doi.org/10.3390/ijerph17031729
9. Wang C, Pan R, Wan X, Tan Y, Xu L, McIntyre RS et al (2020) A longitudinal study on the mental health of general population during the COVID-19 epidemic in China. Brain Behav Immun 50:889–51591(20):30511. https://doi.org/10.1016/j.bbi.2020.04.028
10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism initiative. Ann Rheum Dis 69:1580–1588
11. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Forin PR et al (2012) Derivation and validation of the systemic lupus international collaborat‑ ing clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686. https://doi.org/10.1002/art.34473
12. Smolen JS, Breedveld FC, Schiff MH, Kalide JR, Emery P, Eberl G et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology. 42:244–245
13. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, Hahn BH et al (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142:953–962
14. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55
15. Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR (2012) New insights into mechanism of therapeutic effect of antimalarial agents in SLE. Nat Rev Rheumatol 8:522–533
16. The HERA Study Group (1995) A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Arthritis Rheum 98(2):156–168. https://doi.org/10.1002/1529-0131(199502)25:2<156::AID-ARHE988>3.0.CO;2-L
17. McIntees IB (2020) Covid-19 and rheumatology: first steps towards differ‑ ent future? Ann Rheum 79:S1–S2
18. Peterson S, Percy J, Blackburn S, Sullivan E, Karyekar C, Li N (2019) The multifaceted impact of anxiety and depression on patients with...
rheumatoid arthritis. BMC Rheumatol 3:43. https://doi.org/10.1186/s41927-019-0092-5

19. Mehta B, Salmon J, Ibrahim S (2020) Potential shortage of Hydroxychloroquine for patients with lupus during corona virus disease 2019 pandemic. AMA Health Forum 1(4):e200438. https://doi.org/10.1001/jamahealthforum.2020.0438

20. Abualfadl E, Faten I, El Sheereef RR, Hassan E, Tharwat S, Mohamed EF et al (2020) Impact of COVID-19 pandemic on rheumatoid arthritis from a multi-Centre patient-reported questionnaire survey: influence of gender, rural–urban gap and north–south gradient. Rheumatol Int 1:1–9. https://doi.org/10.1007/s00296-020-04736-9

21. Mendel A, Bernatsky S, Askanas a, Bae SC, Clarke AE, Costedoat-Chalumeau N et al (2021) Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the systemic lupus international collaborating clinics. Ann Rheum Dis 80:2. https://doi.org/10.1136/annrheumdis-2020-218164

22. Gheita TA, Salem MN, Eesa NN, Khalil NM, Gamal NM, Abdel Noor R et al (2020) Rheumatologists’ practice during the coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt. Rheumatol Int 40:1599–1611. https://doi.org/10.1007/s00296-020-04655-9

23. Tisseverasinghe A, Peschken C, Hitchon C (2018) Anxiety and mood disorders in systemic lupus erythematosus: current insights and future directions. Curr Rheumatol Rep 20:85

24. Pawlak CR, Witte T, Heiken H, Hundt M, Schubert J, Wese B et al (2003) Flares in patients with systemic lupus erythematosus are associated with daily psychological stress. Psychogeriat Psychosom 72:159–165

25. Tee CA, Salido EO, Reyes PWC, Ho RC, Tee ML (2020) Psychological state and associated factors during the 2019 coronavirus disease (COVID-19) pandemic among Filipinos with rheumatoid arthritis or systemic lupus erythematosus. Open Access Rheumatol Res Rev 2020(12):215–222

26. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html. Accessed 11 Aug.

27. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 20:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.